{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:55:48Z","timestamp":1766022948161,"version":"3.48.0"},"reference-count":202,"publisher":"e-Century Publishing Corporation","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/ymeu1808","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:02:40Z","timestamp":1743134560000},"page":"1580-1603","source":"Crossref","is-referenced-by-count":1,"title":["Druggable upregulated proteins in EWS-FLI-driven Ewing sarcoma as emerging new therapeutic targets"],"prefix":"10.62347","volume":"17","author":[{"given":"Moinuddin","family":"Jiauddin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Sbaraglia M, Righi A, Gambarotti M and Dei Tos AP. Ewing sarcoma and Ewing-like tumors. Virchows Arch 2020; 476: 109-119.","DOI":"10.1007\/s00428-019-02720-8"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Zöllner SK, Amatruda JF, Bauer S, Collaud S, de Álava E, DuBois SG, Hardes J, Hartmann W, Kovar H, Metzler M, Shulman DS, Streitbürger A, Timmermann B, Toretsky JA, Uhlenbruch Y, Vieth V, Grünewald TGP and Dirksen U. Ewing sarcoma-diagnosis, treatment, clinical challenges and future perspectives. J Clin Med 2021; 10: 1685.","DOI":"10.3390\/jcm10081685"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Shi J, Yang J, Ma X and Wang X. Risk factors for metastasis and poor prognosis of Ewing sarcoma: a population based study. J Orthop Surg Res 2020; 15: 88.","DOI":"10.1186\/s13018-020-01607-8"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Flores G and Grohar PJ. One oncogene, several vulnerabilities: EWS\/FLI targeted therapies for Ewing sarcoma. J Bone Oncol 2021; 31: 100404.","DOI":"10.1016\/j.jbo.2021.100404"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Matsumoto Y, Tanaka K, Nakatani F, Matsunobu T, Matsuda S and Iwamoto Y. Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1)regulatory genes. Br J Cancer 2001; 84: 768-775.","DOI":"10.1054\/bjoc.2000.1652"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Svoboda LK, Harris A, Bailey NJ, Schwentner R, Tomazou E, von Levetzow C, Magnuson B, Ljungman M, Kovar H and Lawlor ER. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs. Epigenetics 2014; 9: 1613-1625.","DOI":"10.4161\/15592294.2014.988048"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Desmaze C, Brizard F, Turc-Carel C, Melot T, Delattre O, Thomas G and Aurias A. Multiple chromosomal mechanisms generate an EWS\/FLI1 or an EWS\/ERG fusion gene in Ewing tumors. Cancer Genet Cytogenet 1997; 97: 12-9.","DOI":"10.1016\/S0165-4608(96)00326-3"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Selvanathan SP, Graham GT, Erkizan H V, Dirksen U, Natarajan TG, Dakic A, Yu S, Liu X, Paulsen MT, Ljungman ME, Wu CH, Lawlor ER, Üren A and Toretsky JA. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing. Proc Natl Acad Sci U S A 2015; 112: E1307-16.","DOI":"10.1073\/pnas.1500536112"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Apfelbaum AA, Wrenn ED and Lawlor ER. The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: a review. Front Oncol 2022; 12: 1044707.","DOI":"10.3389\/fonc.2022.1044707"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Pinkerton CR, Bataillard A, Guillo S, Oberlin O, Fervers B and Philip T. Treatment strategies for metastatic Ewing’s sarcoma. Eur J Cancer 2001; 37: 1338-44.","DOI":"10.1016\/S0959-8049(01)00131-9"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Potratz J, Dirksen U, Jürgens H and Craft A. Ewing sarcoma: clinical state-of-the-art. Pediatr Hematol Oncol 2012; 29: 1-11.","DOI":"10.3109\/08880018.2011.622034"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Tsuda Y, Zhang L, Meyers P, Tap WD, Healey JH and Antonescu CR. The clinical heterogeneity of round cell sarcomas with EWSR1\/FUS gene fusions: impact of gene fusion type on clinical features and outcome. Genes Chromosomes Cancer 2020; 59: 525-534.","DOI":"10.1002\/gcc.22857"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Ferrari S, Bertoni F, Mercuri M, Sottili S, Versari M and Bacci G. Ewing’s sarcoma of bone: relation between clinical characteristics and staging. Oncol Rep 2001; 8: 553-556.","DOI":"10.3892\/or.8.3.553"},{"key":"ref13","unstructured":"Sindhu II, Mehreen A, Wali RM and Abubakar M. Clinical outcome of paediatric ewing sarcoma and significance of pathological necrosis for mortality after neoadjuvant chemotherapy: single institutional study. J Pak Med Assoc 2021; 71: 2344-23449."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA and Healey JH. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 1998; 80: 1020-1033.","DOI":"10.2106\/00004623-199807000-00011"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Picci P, Rougraff BT, Bacci G, Neff JR, Sangiorgi L, Cazzola A, Baldini N, Ferrari S, Mercuri M, Ruggieri P, Caldora P, Benassi MS, Fabbri N, Monti C and Campanacci M. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing’s sarcoma of the extremities. J Clin Oncol 1993; 11: 1763-1769.","DOI":"10.1200\/JCO.1993.11.9.1763"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Rodriguez-Galindo C, Spunt SL and Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol 2003; 40: 276-287.","DOI":"10.1002\/mpo.10240"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Werier J, Yao X, Caudrelier JM, Di Primio G, Ghert M, Gupta AA, Kandel R and Verma S. A systematic review of optimal treatment strategies for localized Ewing’s sarcoma of bone after neo-adjuvant chemotherapy. Surg Oncol 2016; 25: 16-23.","DOI":"10.1016\/j.suronc.2015.11.002"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJH, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ and Miser JS. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348: 694-701.","DOI":"10.1056\/NEJMoa020890"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Fayzullina D, Tsibulnikov S, Stempen M, Schroeder BA, Kumar N, Kharwar RK, Acharya A, Timashev P and Ulasov I. Novel targeted therapeutic strategies for Ewing sarcoma. Cancers (Basel) 2022; 14: 1988.","DOI":"10.3390\/cancers14081988"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Chaturvedi A, Hoffman LM, Jensen CC, Lin YC, Grossmann AH, Randall RL, Lessnick SL, Welm AL and Beckerle MC. Molecular dissection of the mechanism by which EWS\/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma. Mol Biol Cell 2014; 25: 2695-709.","DOI":"10.1091\/mbc.e14-01-0007"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Mo J, Tan K, Dong Y, Lu W, Liu F, Mei Y, Huang H, Zhao K, Lv Z, Ye Y and Tang Y. Therapeutic targeting the oncogenic driver EWSR1::FLI1 in Ewing sarcoma through inhibition of the FACT complex. Oncogene 2023; 42: 11-25.","DOI":"10.1038\/s41388-022-02533-1"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Eliazer S, Spencer J, Ye D, Olson E and Ilaria RL. Alteration of mesodermal cell differentiation by EWS\/FLI-1, the oncogene implicated in Ewing’s sarcoma. Mol Cell Biol 2003; 23: 482-92.","DOI":"10.1128\/MCB.23.2.482-492.2003"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR and Lessnick SL. Expression profiling of EWS\/FLI identifies NKX2.2 as a critical target gene in Ewing’s sarcoma. Cancer Cell 2006; 9: 405-416.","DOI":"10.1016\/j.ccr.2006.04.004"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Uchiumi F, Miyazaki S and Tanuma S. The possible functions of duplicated ets (GGAA) motifs located near transcription start sites of various human genes. Cell Mol Life Sci 2011; 68: 2039-51.","DOI":"10.1007\/s00018-011-0674-x"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Yasir M, Park J and Chun W. EWS\/FLI1 characterization, activation, repression, target genes and therapeutic opportunities in Ewing sarcoma. Int J Mol Sci 2023; 24: 15173.","DOI":"10.3390\/ijms242015173"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Martinez-Lage M, Torres-Ruiz R, Puig-Serra P, Moreno-Gaona P, Martin MC, Moya FJ, Quintana-Bustamante O, Garcia-Silva S, Carcaboso AM, Petazzi P, Bueno C, Mora J, Peinado H, Segovia JC, Menendez P and Rodriguez-Perales S. In vivo CRISPR\/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells. Nat Commun 2020; 11: 5060.","DOI":"10.1038\/s41467-020-18875-x"},{"key":"ref27","unstructured":"Kovar H, Aryee DN, Jug G, Henöckl C, Schemper M, Delattre O, Thomas G and Gadner H. EWS\/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 1996; 7: 429-37."},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Palombo R, Frisone P, Fidaleo M, Mercatelli N, Sette C and Paronetto MP. The promoter-associated noncoding RNA pncCCND1_B assembles a protein-RNA complex to regulate cyclin D1 transcription in Ewing sarcoma. Cancer Res 2019; 79: 3570-3582.","DOI":"10.1158\/0008-5472.CAN-18-2403"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Dauphinot L, De Oliveira C, Melot T, Sevenet N, Thomas V, Weissman BE and Delattre O. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene 2001; 20: 3258-3265.","DOI":"10.1038\/sj.onc.1204437"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Fuchs B, Inwards CY and Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing’s sarcoma. Clin Cancer Res 2004; 10: 1344-1353.","DOI":"10.1158\/1078-0432.CCR-03-0038"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Toretsky JA, Kalebic T, Blakesley V, LeRoith D and Helman LJ. The insulin-like growth factor-I receptor is required for EWS\/FLI-1 transformation of fibroblasts. J Biol Chem 1997; 272: 30822-30827.","DOI":"10.1074\/jbc.272.49.30822"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Tirado OM, Mateo-Lozano S, Villar J, Dettin LE, Llort A, Gallego S, Ban J, Kovar H and Notario V. Caveolin-1 (CAV1) is a target of EWS\/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing’s sarcoma cells. Cancer Res 2006; 66: 9937-9947.","DOI":"10.1158\/0008-5472.CAN-06-0927"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Zwerner JP and May WA. PDGF-C is an EWS\/FLI induced transforming growth factor in Ewing family tumors. Oncogene 2001; 20: 626-633.","DOI":"10.1038\/sj.onc.1204133"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Zhang HF, Hughes CS, Li W, He JZ, Surdez D, El-Naggar AM, Cheng H, Prudova A, Delaidelli A, Negri GL, Li X, Ørum-Madsen MS, Lizardo MM, Oo HZ, Colborne S, Shyp T, Scopim-Ribeiro R, Hammond CA, Dhez AC, Langman S, Lim JKM, Kung SHY, Li A, Steino A, Daugaard M, Parker SJ, Geltink RIK, Orentas RJ, Xu LY, Morin GB, Delattre O, Dimitrov DS and Sorensen PH. Proteomic screens for suppressors of Anoikis identify IL1RAP as a promising surface target in Ewing sarcoma. Cancer Discov 2021; 11: 2884-2903.","DOI":"10.1158\/2159-8290.CD-20-1690"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Yang L, Hu HM, Zielinska-Kwiatkowska A and Chansky HA. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing’s sarcoma cells. Biochem Biophys Res Commun 2010; 402: 129-134.","DOI":"10.1016\/j.bbrc.2010.09.129"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Nakatani F, Tanaka K, Sakimura R, Matsumoto Y, Matsunobu T, Li X, Hanada M, Okada T and Iwamoto Y. Identification of p21WAF1\/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 2003; 278: 15105-15115.","DOI":"10.1074\/jbc.M211470200"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Boro A, Prêtre K, Rechfeld F, Thalhammer V, Oesch S, Wachtel M, Schäfer BW and Niggli FK. Small-molecule screen identifies modulators of EWS\/FLI1 target gene expression and cell survival in Ewing’s sarcoma. Int J Cancer 2012; 131: 2153-2164.","DOI":"10.1002\/ijc.27472"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Cidre-Aranaz F, Grünewald TGP, Surdez D, García-García L, Carlos Lázaro J, Kirchner T, González-González L, Sastre A, García-Miguel P, López-Pérez SE, Monzón S, Delattre O and Alonso J. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma. Oncogene 2017; 36: 766-776.","DOI":"10.1038\/onc.2016.244"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Hahm KB, Cho K, Lee C, Im YH, Chang J, Choi SG, Sorensen PHB, Thiele CJ and Kim SJ. Repression of the gene encoding the TGF-β type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 1999; 23: 222-227.","DOI":"10.1038\/13854"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Jully B, Vijayalakshmi R, Gopal G, Sabitha K and Rajkumar T. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing’s sarcoma in vitro. BMC Cancer 2012; 12: 513.","DOI":"10.1186\/1471-2407-12-513"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Uren A, Tcherkasskaya O and Toretsky JA. Recombinant EWS-FLI1 oncoprotein activates transcription. Biochemistry 2004; 43: 13579-89.","DOI":"10.1021\/bi048776q"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Mandal S, Moudgil M and Mandal SK. Rational drug design. Eur J Pharmacol 2009; 625: 90-100.","DOI":"10.1016\/j.ejphar.2009.06.065"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Wu CC, Beird HC, Zhang J and Futreal PA. FusionPathway: prediction of pathways and therapeutic targets associated with gene fusions in cancer. PLoS Comput Biol 2018; 14: e1006266.","DOI":"10.1371\/journal.pcbi.1006266"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Barber-Rotenberg JS, Selvanathan SP, Kong Y, Erkizan HV, Snyder TM, Hong SP, Kobs CL, South NL, Summer S, Monroe PJ, Chruszcz M, Dobrev V, Tosso PN, Scher LJ, Minor W, Brown ML, Metallo SJ, Üren A and Toretsky JA. Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget 2012; 3: 172-82.","DOI":"10.18632\/oncotarget.454"},{"key":"ref45","unstructured":"Ramachandran B, Rajkumar T and Gopisetty G. Challenges in modeling EWS-FLI1-driven transgenic mouse model for Ewing sarcoma. Am J Transl Res 2021; 13: 12181."},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Minas TZ, Surdez D, Javaheri T, Tanaka M, Howarth M, Kang HJ, Han J, Han ZY, Sax B, Kream BE, Hong SH, çelik H, Tirode F, Tuckermann J, Toretsky JA, Kenner L, Kovar H, Lee S, Sweet-Cordero EA, Nakamura T, Moriggl R, Delattre O and Üren A. Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget 2017; 8: 34141-34163.","DOI":"10.18632\/oncotarget.9388"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Huang X, Park H, Greene J, Pao J, Mulvey E, Zhou SX, Albert CM, Moy F, Sachdev D, Yee D, Rader C, Hamby CV, Loeb DM, Cairo MS and Zhou X. IGF1R- and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas. PLoS One 2015; 10: e0133152.","DOI":"10.1371\/journal.pone.0133152"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Pfister AS, Tanneberger K, Schambony A and Behrens J. Amer2 protein is a novel negative regulator of Wnt\/β-catenin signaling involved in neuroectodermal patterning. J Biol Chem 2012; 287: 1734-41.","DOI":"10.1074\/jbc.M111.308650"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, Marina N, Leavey P, Gebhardt M, Healey J, Shamberger RC, Goorin A, Miser J, Meyer J, Arndt CAS, Sailer S, Marcus K, Perlman E, Dickman P and Grier HE. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol 2009; 27: 2536-2541.","DOI":"10.1200\/JCO.2008.19.1478"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Brennan B, Kirton L, Marec-Bérard P, Gaspar N, Laurence V, Martín-Broto J, Sastre A, Gelderblom H, Owens C, Fenwick N, Strauss S, Moroz V, Whelan J and Wheatley K. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. Lancet 2022; 400: 1513-1521.","DOI":"10.1016\/S0140-6736(22)01790-1"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Zöllner SK, Selvanathan SP, Graham GT, Commins RMT, Hong SH, Moseley E, Parks S, Haladyna JN, Erkizan HV, Dirksen U, Hogarty MD, Üren A and Toretsky JA. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing’s sarcoma. Sci Signal 2017; 10: eaam8429.","DOI":"10.1126\/scisignal.aam8429"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Lenaz L and Page JA. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 1976; 3: 111-20.","DOI":"10.1016\/S0305-7372(76)80018-7"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Arrieta Ó, Medina LA, Estrada-Lobato E, Hernández-Pedro N, Villanueva-Rodríguez G, Martínez-Barrera L, Macedo EO, López-Rodríguez V, Motola-Kuba D and Corona-Cruz JF. First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br J Cancer 2012; 106: 1027-32.","DOI":"10.1038\/bjc.2012.44"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Garcia H, Miecznikowski JC, Safina A, Commane M, Ruusulehto A, Kilpinen S, Leach RW, Attwood K, Li Y, Degan S, Omilian AR, Guryanova O, Papantonopoulou O, Wang J, Buck M, Liu S, Morrison C and Gurova KV. Facilitates chromatin transcription complex is an “accelerator” of tumor transformation and potential marker and target of aggressive cancers. Cell Rep 2013; 4: 159-73.","DOI":"10.1016\/j.celrep.2013.06.013"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Xiang YY, Wang DY, Tanaka M, Igarashi H, Naito Y, Ohtawara Y, Shen Q and Sugimura H. Expression of structure-specific recognition protein mRNA in fetal kidney and Fe-nitrilotriacetate-induced renal carcinoma in the rat. Cancer Lett 1996; 106: 271-8.","DOI":"10.1016\/0304-3835(96)04332-7"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Garcia H, Fleyshman D, Kolesnikova K, Safina A, Commane M, Paszkiewicz G, Omelian A, Morrison C and Gurova K. Expression of FACT in mammalian tissues suggests its role in maintaining of undifferentiated state of cells. Oncotarget 2011; 2: 783-96.","DOI":"10.18632\/oncotarget.340"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Hudson ME, Pozdnyakova I, Haines K, Mor G and Snyder M. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci U S A 2007; 104: 17494-9.","DOI":"10.1073\/pnas.0708572104"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M, Bosykh DA, Commane M, Guryanova OA, Pal S, Safina A, Sviridov S, Koman IE, Veith J, Komar AA, Gudkov AV and Gurova KV. Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Sci Transl Med 2011; 3: 95ra74.","DOI":"10.1126\/scitranslmed.3002530"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Koman IE, Commane M, Paszkiewicz G, Hoonjan B, Pal S, Safina A, Toshkov I, Purmal AA, Wang D, Liu S, Morrison C, Gudkov AV and Gurova KV. Targeting FACT complex suppresses mammary tumorigenesis in Her2\/neu transgenic mice. Cancer Prev Res (Phila) 2012; 5: 1025-35.","DOI":"10.1158\/1940-6207.CAPR-11-0529"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Carter DR, Murray J, Cheung BB, Gamble L, Koach J, Tsang J, Sutton S, Kalla H, Syed S, Gifford AJ, Issaeva N, Biktasova A, Atmadibrata B, Sun Y, Sokolowski N, Ling D, Kim PY, Webber H, Clark A, Ruhle M, Liu B, Oberthuer A, Fischer M, Byrne J, Saletta F, Thwe LM, Purmal A, Haderski G, Burkhart C, Speleman F, De Preter K, Beckers A, Ziegler DS, Liu T, Gurova KV, Gudkov AV, Norris MD, Haber M and Marshall GM. Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Sci Transl Med 2015; 7: 312ra176.","DOI":"10.1126\/scitranslmed.aab1803"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Fetisov TI, Borunova AA, Antipova AS, Antoshina EE, Trukhanova LS, Gorkova TG, Zuevskaya SN, Maslov A, Gurova K, Gudkov A, Lesovaya EA, Belitsky GA, Yakubovskaya MG and Kirsanov KI. Targeting features of curaxin CBL0137 on hematological malignancies in vitro and in vivo. Biomedicines 2023; 11: 230.","DOI":"10.3390\/biomedicines11010230"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Seong BKA, Dharia NV, Lin S, Donovan KA, Chong S, Robichaud A, Conway A, Hamze A, Ross L, Alexe G, Adane B, Nabet B, Ferguson FM, Stolte B, Wang EJ, Sun J, Darzacq X, Piccioni F, Gray NS, Fischer ES and Stegmaier K. TRIM8 modulates the EWS\/FLI oncoprotein to promote survival in Ewing sarcoma. Cancer Cell 2021; 39: 1262-1278.e7.","DOI":"10.1016\/j.ccell.2021.07.003"},{"key":"ref63","unstructured":"Toretsky JA, Thakar M, Eskenazi AE and Frantz CN. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing’s sarcoma family of tumors. Cancer Res 1999; 59: 5745-50."},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Pilarsky C, Wenzig M, Specht T, Saeger HD and Grützmann R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 2004; 6: 744-50.","DOI":"10.1593\/neo.04277"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Voigt E and Quelle DE. FOXM1, MEK, and CDK4\/6: new targets for malignant peripheral nerve sheath tumor therapy. Int J Mol Sci 2023; 24: 13596.","DOI":"10.3390\/ijms241713596"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Aimaier R, Chung MH, Gu Y, Yu Q, Wei C, Li H, Guo Z, Long M, Li Y, Wang W, Li Q and Wang Z. FOXM1 promotes neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor progression in a NUF2-dependent manner. Cancer Gene Ther 2023; 30: 1390-1402.","DOI":"10.1038\/s41417-023-00645-8"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Maekawa A, Kohashi K, Kuda M, Iura K, Ishii T, Endo M, Nakatsura T, Iwamoto Y and Oda Y. Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas. BMC Cancer 2016; 16: 511.","DOI":"10.1186\/s12885-016-2542-4"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Shi S, Wang Q and Du X. Comprehensive bioinformatics analysis reveals the oncogenic role of FoxM1 and its impact on prognosis, immune microenvironment, and drug sensitivity in osteosarcoma. J Appl Genet 2023; 64: 779-796.","DOI":"10.1007\/s13353-023-00785-5"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Kuda M, Kohashi K, Yamada Y, Maekawa A, Kinoshita Y, Nakatsura T, Iwamoto Y, Taguchi T and Oda Y. FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target. Tumour Biol 2016; 37: 5213-23.","DOI":"10.1007\/s13277-015-4351-9"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D’Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F and Ravaggi A. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. J Exp Clin Cancer Res 2017; 36: 63.","DOI":"10.1186\/s13046-017-0536-y"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Abdeljaoued S, Bettaieb I, Nasri M, Adouni O, Goucha A, El Amine O, Boussen H, Rahal K and Gamoudi A. Overexpression of FOXM1 is a potential prognostic marker in male breast cancer. Oncol Res Treat 2017; 40: 167-172.","DOI":"10.1159\/000458156"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Liu Y, Liu Y, Yuan B, Yin L, Peng Y, Yu X, Zhou W, Gong Z, Liu J, He L and Li X. FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription. Oncotarget 2017; 8: 17027-17037.","DOI":"10.18632\/oncotarget.15224"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Zhang H, Zhong H, Li L, Ji W and Zhang X. Overexpressed transcription factor FOXM1 contributes to the progression of colorectal cancer. Mol Med Rep 2016; 13: 2696-700.","DOI":"10.3892\/mmr.2016.4875"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Kong FF, Qu ZQ, Yuan HH, Wang JY, Zhao M, Guo YH, Shi J, Gong XD, Zhu YL, Liu F, Zhang WY and Jiang B. Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer. Oncol Rep 2014; 31: 2660-8.","DOI":"10.3892\/or.2014.3129"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Okada K, Fujiwara Y, Takahashi T, Nakamura Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y and Mori M, Doki Y. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer. Ann Surg Oncol 2013; 20: 1035-43.","DOI":"10.1245\/s10434-012-2680-0"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Egawa M, Yoshida Y, Ogura S, Kurahashi T, Kizu T, Furuta K, Kamada Y, Chatani N, Hamano M, Kiso S, Hikita H, Tatsumi T, Eguchi H, Nagano H, Doki Y, Mori M and Takehara T. Increased expression of Forkhead box M1 transcription factor is associated with clinicopathological features and confers a poor prognosis in human hepatocellular carcinoma. Hepatol Res 2017; 47: 1196-1205.","DOI":"10.1111\/hepr.12854"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Ito T, Kohashi K, Yamada Y, Iwasaki T, Maekawa A, Kuda M, Hoshina D, Abe R, Furue M and Oda Y. Prognostic significance of Forkhead Box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in angiosarcoma. J Cancer 2016; 7: 823-30.","DOI":"10.7150\/jca.14461"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Chen YJ, Dominguez-Brauer C, Wang Z, Asara JM, Costa RH, Tyner AL, Lau LF and Raychaudhuri P. A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1. J Biol Chem 2009; 284: 30695-707.","DOI":"10.1074\/jbc.M109.007997"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Schimmel J, Eifler K, Sigurðsson JO, Cuijpers SA, Hendriks IA, Verlaan-de Vries M, Kelstrup CD, Francavilla C, Medema RH, Olsen JV and Vertegaal AC. Uncovering SUMOylation dynamics during cell-cycle progression reveals FoxM1 as a key mitotic SUMO target protein. Mol Cell 2014; 53: 1053-66.","DOI":"10.1016\/j.molcel.2014.02.001"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Lv C, Zhao G, Sun X, Wang P, Xie N, Luo J and Tong T. Acetylation of FOXM1 is essential for its transactivation and tumor growth stimulation. Oncotarget 2016; 7: 60366-60382.","DOI":"10.18632\/oncotarget.11332"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Wang K, Zhu X, Zhang K, Zhu L and Zhou F. FoxM1 inhibition enhances chemosensitivity of docetaxel-resistant A549 cells to docetaxel via activation of JNK\/mitochondrial pathway. Acta Biochim Biophys Sin (Shanghai) 2016; 48: 804-9.","DOI":"10.1093\/abbs\/gmw072"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, Diehn M, West RB, Plevritis SK and Alizadeh AA. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015; 21: 938-945.","DOI":"10.1038\/nm.3909"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Christensen L, Joo J, Lee S, Wai D, Triche TJ and May WA. FOXM1 is an oncogenic mediator in Ewing sarcoma. PLoS One 2013; 8: e54556.","DOI":"10.1371\/journal.pone.0054556"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Wang SP, Wu SQ, Huang SH, Tang YX, Meng LQ, Liu F, Zhu QH and Xu YG. FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair. Cell Death Dis 2021; 12: 1138.","DOI":"10.1038\/s41419-021-04434-9"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Shukla S, Milewski D, Pradhan A, Rama N, Rice K, Le T, Flick MJ, Vaz S, Zhao X, Setchell KD, Logarinho E, Kalinichenko VV and Kalin TV. The FOXM1 inhibitor RCM-1 decreases carcinogenesis and nuclear β-catenin. Mol Cancer Ther 2019; 18: 1217-1229.","DOI":"10.1158\/1535-7163.MCT-18-0709"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Shim JK, Lim SH, Jeong JH, Choi RJ, Oh Y, Park J, Choi S, Hong J, Kim SJ, Moon JH, Kim EH, Teo WY, Park BJ, Chang JH, Ryu JH and Kang SG. A lignan from Alnus japonica inhibits glioblastoma tumorspheres by suppression of FOXM1. Sci Rep 2022; 12: 13990.","DOI":"10.1038\/s41598-022-18185-w"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Sengupta A, Rahman M, Mateo-Lozano S, Tirado OM and Notario V. The dual inhibitory effect of thiostrepton on FoxM1 and EWS\/FLI1 provides a novel therapeutic option for Ewing’s sarcoma. Int J Oncol 2013; 43: 803-12.","DOI":"10.3892\/ijo.2013.2016"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Liu XF, Li XY, Zheng PS and Yang WT. DAX1 promotes cervical cancer cell growth and tumorigenicity through activation of Wnt\/β-catenin pathway via GSK3β. Cell Death Dis 2018; 9: 339.","DOI":"10.1038\/s41419-018-0359-6"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"García-Aragoncillo E, Carrillo J, Lalli E, Agra N, Gómez-López G, Pestaña A, Alonso J. DAX1, a direct target of EWS\/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing’s tumor cells. Oncogene 2008; 27: 6034-43.","DOI":"10.1038\/onc.2008.203"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Kinsey M, Smith R and Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS\/FLI in Ewing’s sarcoma. Mol Cancer Res 2006; 4: 851-9.","DOI":"10.1158\/1541-7786.MCR-06-0090"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Mendiola M, Carrillo J, García E, Lalli E, Hernández T, de Alava E, Tirode F, Delattre O, García-Miguel P, López-Barea F, Pestaña A and Alonso J. The orphan nuclear receptor DAX1 is up-regulated by the EWS\/FLI1 oncoprotein and is highly expressed in Ewing tumors. Int J Cancer 2006; 118: 1381-9.","DOI":"10.1002\/ijc.21578"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Kinsey M, Smith R, Iyer AK, McCabe ER and Lessnick SL. EWS\/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing’s sarcoma. Cancer Res 2009; 69: 9047-55.","DOI":"10.1158\/0008-5472.CAN-09-1540"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Bar-Peled L, Kemper EK, Suciu RM, Vinogradova EV, Backus KM, Horning BD, Paul TA, Ichu TA, Svensson RU, Olucha J, Chang MW, Kok BP, Zhu Z, Ihle NT, Dix MM, Jiang P, Hayward MM, Saez E, Shaw RJ and Cravatt BF. Chemical proteomics identifies druggable vulnerabilities in a genetically defined cancer. Cell 2017; 171: 696-709, e23.","DOI":"10.1016\/j.cell.2017.08.051"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Lu Y, Liu Y, Liao S, Tu W, Shen Y, Yan Y, Tao D, Lu Y, Ma Y, Yang Y and Zhang S. Epigenetic modifications promote the expression of the orphan nuclear receptor NR0B1 in human lung adenocarcinoma cells. Oncotarget 2016; 7: 43162-43176.","DOI":"10.18632\/oncotarget.9012"},{"key":"ref95","unstructured":"Chang WI, Honeyman JN, Zhang J, Lin C, Sharma A, Zhou L, Oliveira J, Tapinos N, Lulla RR, Prabhu VV and El-Deiry WS. Novel combination of imipridones and histone deacetylase inhibitors demonstrate cytotoxic effect through integrated stress response in pediatric solid tumors. Am J Cancer Res 2023; 13: 6241-6255."},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Dalal S, Berry AM, Cullinane CJ, Mangham DC, Grimer R, Lewis IJ, Johnston C, Laurence V and Burchill SA. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing’s sarcoma family. Clin Cancer Res 2005; 11: 2364-78.","DOI":"10.1158\/1078-0432.CCR-04-1201"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, Hicklin DJ and Kleinerman ES. Suppression of Ewing’s sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res 2007; 13: 4867-73.","DOI":"10.1158\/1078-0432.CCR-07-0133"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Wang Y, Pandey RN, Roychoudhury K, Milewski D, Kalin TV, Szabo S, Pressey JG and Hegde RS. Targeting EYA3 in Ewing sarcoma retards tumor growth and angiogenesis. Mol Cancer Ther 2021; 20: 803-815.","DOI":"10.1158\/1535-7163.MCT-20-0749"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Ackermann M, Morse BA, Delventhal V, Carvajal IM and Konerding MA. Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing’s sarcoma A673-xenograft growth and normalize tumor vascular architecture. Angiogenesis 2012; 15: 685-95.","DOI":"10.1007\/s10456-012-9294-9"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Murai J, Thomas A, Miettinen M and Pommier Y. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. Pharmacol Ther 2019; 201: 94-102.","DOI":"10.1016\/j.pharmthera.2019.05.009"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Croushore EE, Koppenhafer SL, Goss KL, Geary EL and Gordon DJ. Activator Protein-1 (AP-1) signaling inhibits the growth of Ewing sarcoma cells in response to DNA replication stress. Cancer Res Commun 2023; 3: 1580-1593.","DOI":"10.1158\/2767-9764.CRC-23-0268"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Bhosale PB, Kim HH, Abusaliya A, Vetrivel P, Ha SE, Park MY, Lee HJ and Kim GS. Structural and functional properties of activator Protein-1 in cancer and inflammation. Evid Based Complement Alternat Med 2022; 2022: 9797929.","DOI":"10.1155\/2022\/9797929"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Wang Q, Zhu G, Lin C, Lin P, Chen H, He R, Huang Y, Yang S and Ye J. Vimentin affects colorectal cancer proliferation, invasion, and migration via regulated by activator protein 1. J Cell Physiol 2021; 236: 7591-7604.","DOI":"10.1002\/jcp.30402"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Li F, Tian J, Zhang L, He H and Song D. A multi-omics approach to reveal critical mechanisms of activator protein 1 (AP-1). Biomed Pharmacother 2024; 178: 117225.","DOI":"10.1016\/j.biopha.2024.117225"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Kamide D, Yamashita T, Araki K, Tomifuji M, Tanaka Y, Tanaka S, Shiozawa S and Shiotani A. Selective activator protein-1 inhibitor T-5224 prevents lymph node metastasis in an oral cancer model. Cancer Sci 2016; 107: 666-73.","DOI":"10.1111\/cas.12914"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Song D, He H, Sinha I, Hases L, Yan F, Archer A, Haldosen LA, Zhao C and Williams C. Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor. Cancer Lett 2021; 506: 23-34.","DOI":"10.1016\/j.canlet.2021.02.018"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"Watt AC, Cejas P, DeCristo MJ, Metzger-Filho O, Lam EYN, Qiu X, BrinJones H, Kesten N, Coulson R, Font-Tello A, Lim K, Vadhi R, Daniels VW, Montero J, Taing L, Meyer CA, Gilan O, Bell CC, Korthauer KD, Giambartolomei C, Pasaniuc B, Seo JH, Freedman ML, Ma C, Ellis MJ, Krop I, Winer E, Letai A, Brown M, Dawson MA, Long HW, Zhao JJ and Goel S. CDK4\/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nat Cancer 2021; 2: 34-48.","DOI":"10.1038\/s43018-020-00135-y"},{"key":"ref108","doi-asserted-by":"publisher","unstructured":"Pansy K, Uhl B, Krstic J, Szmyra M, Fechter K, Santiso A, Thüminger L, Greinix H, Kargl J, Prochazka K, Feichtinger J and Deutsch AJ. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. Int J Mol Sci 2021; 22: 13311.","DOI":"10.3390\/ijms222413311"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Landuzzi L, Ruzzi F, Pellegrini E, Lollini PL, Scotlandi K and Manara MC. IL-1 family members in bone sarcomas. Cells 2024; 13: 233.","DOI":"10.3390\/cells13030233"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A and Flørenes VA. High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS One 2012; 7: e38254.","DOI":"10.1371\/journal.pone.0038254"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Kreahling JM, Foroutan P, Reed D, Martinez G, Razabdouski T, Bui MM, Raghavan M, Letson D, Gillies RJ and Altiok S. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PLoS One 2013; 8: e57523.","DOI":"10.1371\/journal.pone.0057523"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"Schmidt M, Rohe A, Platzer C, Najjar A, Erdmann F and Sippl W. Regulation of G2\/M transition by inhibition of WEE1 and PKMYT1 kinases. Molecules 2017; 22: 2045.","DOI":"10.3390\/molecules22122045"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"Squire CJ, Dickson JM, Ivanovic I and Baker EN. Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation. Structure 2005; 13: 541-50.","DOI":"10.1016\/j.str.2004.12.017"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"Choi W and Lee ES. Therapeutic targeting of DNA damage response in cancer. Int J Mol Sci 2022; 23: 1701.","DOI":"10.3390\/ijms23031701"},{"key":"ref115","doi-asserted-by":"publisher","unstructured":"Geenen JJJ and Schellens JHM. Molecular pathways: targeting the protein kinase Wee1 in cancer. Clin Cancer Res 2017; 23: 4540-4544.","DOI":"10.1158\/1078-0432.CCR-17-0520"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"Mackintosh C, García-Domínguez DJ, Ordóñez JL, Ginel-Picardo A, Smith PG, Sacristán MP and de Álava E. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells. Oncogene 2013; 32: 1441-51.","DOI":"10.1038\/onc.2012.153"},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"Martin JC, Sims JR, Gupta A, Bakin AV and Ohm JE. WEE1 inhibition augments CDC7 (DDK) inhibitor-induced cell death in Ewing sarcoma by forcing premature mitotic entry and mitotic catastrophe. Cancer Res Commun 2022; 2: 471-482.","DOI":"10.1158\/2767-9764.CRC-22-0130"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"Yang Y, Liu X, Wang X, Zhang J, Li S and Ma X. Comprehensive analysis of ABCA family members in lung adenocarcinoma with prognostic values. Mol Biotechnol 2022; 64: 1441-1453.","DOI":"10.1007\/s12033-022-00506-z"},{"key":"ref119","doi-asserted-by":"publisher","unstructured":"Shi L, Huang Y, Huang X, Zhou W, Wei J, Deng D and Lai Y. Analyzing the key gene expression and prognostics values for acute myeloid leukemia. Transl Cancer Res 2020; 9: 7284-7298.","DOI":"10.21037\/tcr-20-3177"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"Pasello M, Giudice AM, Cristalli C, Manara MC, Mancarella C, Parra A, Serra M, Magagnoli G, Cidre-Aranaz F, Grünewald TGP, Bini C, Lollini PL, Longhi A, Donati DM and Scotlandi K. ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R\/AKT\/MDM2 axis. Cell Oncol (Dordr) 2022; 45: 1237-1251.","DOI":"10.1007\/s13402-022-00713-5"},{"key":"ref121","doi-asserted-by":"publisher","unstructured":"Wang W, Albadari N, Du Y, Fowler JF, Sang HT, Xian W, McKeon F, Li W, Zhou J and Zhang R. MDM2 inhibitors for cancer therapy: the past, present, and future. Pharmacol Rev 2024; 76: 414-453.","DOI":"10.1124\/pharmrev.123.001026"},{"key":"ref122","doi-asserted-by":"publisher","unstructured":"Chao CC. Mechanisms of p53 degradation. Clin Chim Acta 2015; 438: 139-47.","DOI":"10.1016\/j.cca.2014.08.015"},{"key":"ref123","doi-asserted-by":"publisher","unstructured":"Onel K and Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res 2004; 2: 1-8.","DOI":"10.1158\/1541-7786.1.2.1"},{"key":"ref124","doi-asserted-by":"publisher","unstructured":"Nag S, Zhang X, Srivenugopal KS, Wang MH, Wang W and Zhang R. Targeting MDM2-p53 interaction for cancer therapy: are we there yet? Curr Med Chem 2014; 21: 553-74.","DOI":"10.2174\/09298673113206660325"},{"key":"ref125","doi-asserted-by":"publisher","unstructured":"Konopleva M, Martinelli G, Daver N, Papayannidis C, Wei A, Higgins B, Ott M, Mascarenhas J and Andreeff M. MDM2 inhibition: an important step forward in cancer therapy. Leukemia 2020; 34: 2858-2874.","DOI":"10.1038\/s41375-020-0949-z"},{"key":"ref126","doi-asserted-by":"publisher","unstructured":"Rosso M, Okoro DE and Bargonetti J. Splice variants of MDM2 in oncogenesis. Subcell Biochem 2014; 85: 247-61.","DOI":"10.1007\/978-94-017-9211-0_14"},{"key":"ref127","doi-asserted-by":"publisher","unstructured":"Ladanyi M, Lewis R, Jhanwar SC, Gerald W, Huvos AG and Healey JH. MDM2 and CDK4 gene amplification in Ewing’s sarcoma. J Pathol 1995; 175: 211-7.","DOI":"10.1002\/path.1711750209"},{"key":"ref128","doi-asserted-by":"publisher","unstructured":"Di Conza G, Buttarelli M, Monti O, Pellegrino M, Mancini F, Pontecorvi A, Scotlandi K and Moretti F. IGF-1R\/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells. Mol Cancer Ther 2012; 11: 1247-56.","DOI":"10.1158\/1535-7163.MCT-11-0913"},{"key":"ref129","doi-asserted-by":"publisher","unstructured":"Xue R, Fan Z and An Y. Knockdown of PRDX2 inhibits the proliferation, growth, migration, invasion, and MMP9 activity of Ewing’s sarcoma cells cultured in vitro. Cancer Rep (Hoboken) 2024; 7: e2122.","DOI":"10.1002\/cnr2.2122"},{"key":"ref130","doi-asserted-by":"publisher","unstructured":"Thapa P, Jiang H, Ding N, Hao Y, Alshahrani A and Wei Q. The role of peroxiredoxins in cancer development. Biology (Basel) 2023; 12: 666.","DOI":"10.3390\/biology12050666"},{"key":"ref131","doi-asserted-by":"publisher","unstructured":"Jia W, Chen P and Cheng Y. PRDX4 and its roles in various cancers. Technol Cancer Res Treat 2019; 18: 1533033819864313.","DOI":"10.1177\/1533033819864313"},{"key":"ref132","doi-asserted-by":"publisher","unstructured":"Nicolussi A, D’Inzeo S, Capalbo C, Giannini G and Coppa A. The role of peroxiredoxins in cancer. Mol Clin Oncol 2017; 6: 139-153.","DOI":"10.3892\/mco.2017.1129"},{"key":"ref133","doi-asserted-by":"publisher","unstructured":"Park SY, Lee YJ, Park J, Kim TH, Hong SC, Jung EJ, Ju YT, Jeong CY, Park HJ, Ko GH, Song DH, Park M, Yoo J and Jeong SH. PRDX4 overexpression is associated with poor prognosis in gastric cancer. Oncol Lett 2020; 19: 3522-3530.","DOI":"10.3892\/ol.2020.11468"},{"key":"ref134","doi-asserted-by":"publisher","unstructured":"Wei W, Ma C, Cao Y, Yang L, Huang Z, Qin D, Chen Y, Liu C, Xia L, Wang T, Lei H, Yu Y, Huang M, Tong Y, Xu H, Gao F, Zhang J and Wu YL. Identification of H7 as a novel peroxiredoxin I inhibitor to induce differentiation of leukemia cells. Oncotarget 2016; 7: 3873-83.","DOI":"10.18632\/oncotarget.6763"},{"key":"ref135","doi-asserted-by":"publisher","unstructured":"Chen X, Zhao Y, Luo W, Chen S, Lin F, Zhang X, Fan S, Shen X, Wang Y and Liang G. Celastrol induces ROS-mediated apoptosis via directly targeting peroxiredoxin-2 in gastric cancer cells. Theranostics 2020; 10: 10290-10308.","DOI":"10.7150\/thno.46728"},{"key":"ref136","doi-asserted-by":"publisher","unstructured":"Do K and Chen AP. Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res 2013; 19: 977-84.","DOI":"10.1158\/1078-0432.CCR-12-0163"},{"key":"ref137","doi-asserted-by":"publisher","unstructured":"Cortesi L, Rugo HS and Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol 2021; 16: 255-282.","DOI":"10.1007\/s11523-021-00796-4"},{"key":"ref138","doi-asserted-by":"publisher","unstructured":"Baughan CA. Reversal of vocal cord paralysis by tamoxifen. Clin Oncol (R Coll Radiol) 1990; 2: 367.","DOI":"10.1016\/S0936-6555(05)81003-9"},{"key":"ref139","doi-asserted-by":"publisher","unstructured":"Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, Liu M, Lonigro R, Prensner JR, Tomlins SA and Chinnaiyan AM. PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma. Cancer Res 2012; 72: 1608-13.","DOI":"10.1158\/0008-5472.CAN-11-3648"},{"key":"ref140","doi-asserted-by":"publisher","unstructured":"Lee HJ, Yoon C, Schmidt B, Park DJ, Zhang AY, Erkizan HV, Toretsky JA, Kirsch DG and Yoon SS. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage. Mol Cancer Ther 2013; 12: 2591-600.","DOI":"10.1158\/1535-7163.MCT-13-0338"},{"key":"ref141","doi-asserted-by":"publisher","unstructured":"Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, del Carmen García-Macías M, Sevillano V, Alonso D, Pascual-Pasto G, San-Segundo L, Vila-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J and de Álava E. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. Oncotarget 2015; 6: 18875-90.","DOI":"10.18632\/oncotarget.4303"},{"key":"ref142","doi-asserted-by":"publisher","unstructured":"Cummings CT, Deryckere D, Earp HS and Graham DK. Molecular pathways: MERTK signaling in cancer. Clin Cancer Res 2013; 19: 5275-80.","DOI":"10.1158\/1078-0432.CCR-12-1451"},{"key":"ref143","doi-asserted-by":"publisher","unstructured":"Huelse JM, Fridlyand DM, Earp S, DeRyckere D and Graham DK. MERTK in cancer therapy: targeting the receptor tyrosine kinase in tumor cells and the immune system. Pharmacol Ther 2020; 213: 107577.","DOI":"10.1016\/j.pharmthera.2020.107577"},{"key":"ref144","doi-asserted-by":"publisher","unstructured":"Smart SK, Yeung TY, Santos MO, McSwain LF, Wang X, Frye SV, Earp HS 3rd, DeRyckere D and Graham DK. MERTK is a potential therapeutic target in Ewing sarcoma. Cancers (Basel) 2024; 16: 2831.","DOI":"10.3390\/cancers16162831"},{"key":"ref145","doi-asserted-by":"publisher","unstructured":"Chiappa M, Petrella S, Damia G, Broggini M, Guffanti F and Ricci F. Present and future perspective on PLK1 inhibition in cancer treatment. Front Oncol 2022; 12: 903016.","DOI":"10.3389\/fonc.2022.903016"},{"key":"ref146","doi-asserted-by":"publisher","unstructured":"Gutteridge RE, Ndiaye MA, Liu X and Ahmad N. Plk1 inhibitors in cancer therapy: from laboratory to clinics. Mol Cancer Ther 2016; 15: 1427-35.","DOI":"10.1158\/1535-7163.MCT-15-0897"},{"key":"ref147","doi-asserted-by":"publisher","unstructured":"WeiΔ LM, Hugle M and Fulda S. Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines. Oncotarget 2017; 8: 52445-52456.","DOI":"10.18632\/oncotarget.17190"},{"key":"ref148","doi-asserted-by":"publisher","unstructured":"Li J, Ohmura S, Marchetto A, Orth MF, Imle R, Dallmayer M, Musa J, Knott MML, Hölting TLB, Stein S, Funk CM, Sastre A, Alonso J, Bestvater F, Kasan M, Romero-Pérez L, Hartmann W, Ranft A, Banito A, Dirksen U, Kirchner T, Cidre-Aranaz F and Grünewald TGP. Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer. Nat Commun 2021; 12: 5356.","DOI":"10.1038\/s41467-021-25553-z"},{"key":"ref149","doi-asserted-by":"publisher","unstructured":"Zhang ZB, Cai L, Zheng SG, Xiong Y and Dong JH. Overexpression of caveolin-1 in hepatocellular carcinoma with metastasis and worse prognosis: correlation with vascular endothelial growth factor, microvessel density and unpaired artery. Pathol Oncol Res 2009; 15: 495-502.","DOI":"10.1007\/s12253-008-9144-7"},{"key":"ref150","doi-asserted-by":"publisher","unstructured":"Barresi V, Cerasoli S and Tuccari G. Correlative evidence that tumor cell-derived caveolin-1 mediates angiogenesis in meningiomas. Neuropathology 2008; 28: 472-8.","DOI":"10.1111\/j.1440-1789.2008.00902.x"},{"key":"ref151","doi-asserted-by":"publisher","unstructured":"Yang G, Addai J, Wheeler TM, Frolov A, Miles BJ, Kadmon D and Thompson TC. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol 2007; 38: 1688-95.","DOI":"10.1016\/j.humpath.2007.03.024"},{"key":"ref152","doi-asserted-by":"publisher","unstructured":"Surawska H, Ma PC and Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 2004; 15: 419-33.","DOI":"10.1016\/j.cytogfr.2004.09.002"},{"key":"ref153","doi-asserted-by":"publisher","unstructured":"Hachim IY, Villatoro M, Canaff L, Hachim MY, Boudreault J, Haiub H, Ali S and Lebrun JJ. Author correction: transforming growth factor-beta regulation of ephrin type-a receptor 4 signaling in breast cancer cellular migration. Sci Rep 2022; 12: 21613.","DOI":"10.1038\/s41598-022-24542-6"},{"key":"ref154","doi-asserted-by":"publisher","unstructured":"Kikuchi S, Kaibe N, Morimoto K, Fukui H, Niwa H, Maeyama Y, Takemura M, Matsumoto M, Nakamori S, Miwa H, Hirota S and Sasako M. Overexpression of Ephrin A2 receptors in cancer stromal cells is a prognostic factor for the relapse of gastric cancer. Gastric Cancer 2015; 18: 485-94.","DOI":"10.1007\/s10120-014-0390-y"},{"key":"ref155","doi-asserted-by":"publisher","unstructured":"Giordano G, Merlini A, Ferrero G, Mesiano G, Fiorino E, Brusco S, Centomo ML, Leuci V, D’Ambrosio L, Aglietta M, Sangiolo D, Grignani G and Pignochino Y. EphA2 expression in bone sarcomas: bioinformatic analyses and preclinical characterization in patient-derived models of osteosarcoma, Ewing’s sarcoma and chondrosarcoma. Cells 2021; 10: 2893.","DOI":"10.3390\/cells10112893"},{"key":"ref156","doi-asserted-by":"publisher","unstructured":"Hadjimichael AC, Pergaris A, Kaspiris A, Foukas AF, Kokkali S, Tsourouflis G and Theocharis S. The EPH\/Ephrin system in bone and soft tissue sarcomas’ pathogenesis and therapy: new advancements and a literature review. Int J Mol Sci 2022; 23: 5171.","DOI":"10.3390\/ijms23095171"},{"key":"ref157","unstructured":"Whitsett JA, Burdsall J, Workman L, Hollinger B and Neely J. beta-Adrenergic receptors in pediatric tumors: uncoupled beta 1-adrenergic receptor in Ewing’s sarcoma. J Natl Cancer Inst 1983; 71: 779-86."},{"key":"ref158","doi-asserted-by":"publisher","unstructured":"Rains SL, Amaya CN and Bryan BA. Beta-adrenergic receptors are expressed across diverse cancers. Oncoscience 2017; 4: 95-105.","DOI":"10.18632\/oncoscience.357"},{"key":"ref159","doi-asserted-by":"publisher","unstructured":"Quôc Lu’o’ng KV and Nguyên LT. The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms. Cancer Manag Res 2012; 4: 431-45.","DOI":"10.2147\/CMAR.S39153"},{"key":"ref160","doi-asserted-by":"publisher","unstructured":"Cole SW and Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 2012; 18: 1201-6.","DOI":"10.1158\/1078-0432.CCR-11-0641"},{"key":"ref161","doi-asserted-by":"publisher","unstructured":"Calvani M, Vignoli M, Beltrami G, Pasha A, Scalini P, Mannurita SC, Cardellicchio S, Coccoli L, Cecchi C, Marco E, Luti L, Bernasconi S, Filippi L, Casazza G, Tamburini A and Favre C. Preliminary study on β3-adrenoreceptor as predictor marker of relapse in Ewing sarcoma patients. Biomedicines 2020; 8: 413.","DOI":"10.3390\/biomedicines8100413"},{"key":"ref162","doi-asserted-by":"publisher","unstructured":"Choderlos de Laclos X, Risbourg S, Brennan B, Bertucci F, Gaspar N, Gelderblom H, Hawkins DS, Janeway K, Juergens H, Kasper B, Krailo MD, Cécile Le Deley M, Marec-Bérard P, McCabe MG, Metzler M, Ranft A, Strauss S, Tabone MD, Windsor R, Dirksen U and Gandemer V. Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials. Eur J Cancer 2024; 208: 114229.","DOI":"10.1016\/j.ejca.2024.114229"},{"key":"ref163","doi-asserted-by":"publisher","unstructured":"Duffaud F, Blay JY, Le Cesne A, Chevreau C, Boudou-Rouquette P, Kalbacher E, Penel N, Perrin C, Laurence V, Bompas E, Saada-Bouzid E, Delcambre C, Bertucci F, Cancel M, Schiffler C, Monard L, Bouvier C, Vidal V, Gaspar N and Chabaud S. Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study. Br J Cancer 2023; 129: 1940-1948.","DOI":"10.1038\/s41416-023-02413-9"},{"key":"ref164","doi-asserted-by":"publisher","unstructured":"Casanova M, Bautista F, Campbell-Hewson Q, Makin G, Marshall LV, Verschuur AC, Cañete Nieto A, Corradini N, Ploeger BA, Brennan BJ, Mueller U, Zebger-Gong H, Chung JW and Geoerger B. Regorafenib plus vincristine and irinotecan in pediatric patients with recurrent\/refractory solid tumors: an innovative therapy for children with cancer study. Clin Cancer Res 2023; 29: 4341-4351.","DOI":"10.1158\/1078-0432.CCR-23-0257"},{"key":"ref165","doi-asserted-by":"publisher","unstructured":"Shulman DS, Merriam P, Choy E, Guenther LM, Cavanaugh KL, Kao PC, Posner A, Bhushan K, Fairchild G, Barker E, Klega K, Stegmaier K, Crompton BD, London WB and DuBois SG. Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. Cancer Med 2023; 12: 15207-15216.","DOI":"10.1002\/cam4.6208"},{"key":"ref166","doi-asserted-by":"publisher","unstructured":"Cash T, Jonus HC, Tsvetkova M, Beumer JH, Sadanand A, Lee JY, Henry CJ, Aguilera D, Harvey RD and Goldsmith KC. A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and\/or refractory solid and CNS tumors. Pediatr Blood Cancer 2023; 70: e30405.","DOI":"10.1002\/pbc.30405"},{"key":"ref167","doi-asserted-by":"publisher","unstructured":"DuBois SG, Krailo MD, Glade-Bender J, Buxton A, Laack N, Randall RL, Chen HX, Seibel NL, Boron M, Terezakis S, Hill-Kayser C, Hayes A, Reid JM, Teot L, Rakheja D, Womer R, Arndt C, Lessnick SL, Crompton BD, Kolb EA, Daldrup-Link H, Eutsler E, Reed DR, Janeway KA and Gorlick RG. Randomized phase III trial of ganitumab with interval-compressed chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma: a report from the Children’s oncology group. J Clin Oncol 2023; 41: 2098-2107.","DOI":"10.1200\/JCO.22.01815"},{"key":"ref168","doi-asserted-by":"publisher","unstructured":"Xu J, Xie L, Sun X, Liu K, Liang X, Cai Z, Tang X and Guo W. Longer versus shorter schedules of vincristine, irinotecan, and temozolomide (VIT) for relapsed or refractory Ewing sarcoma: a randomized controlled phase 2 trial. Clin Cancer Res 2023; 29: 1040-1046.","DOI":"10.1158\/1078-0432.CCR-22-3546"},{"key":"ref169","doi-asserted-by":"publisher","unstructured":"Corvest V, Marec-Bérard P, Lervat C, Pacquement H, Toulmonde M, Gentet JC, Laurence V, Cleirec M, Mansuy L, Bompas E, Castex MP, Taque S, Filhon B, Tabone MD, Verité C, Entz-Werle N, Saumet L, Guimard G, Pondrom M, Chevreau C, Flandrin J, Duranteau L, Rousset-Jablonski C, Brugières L, Jimenez M, Le Deley MC, Gaspar N and Fresneau B. Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France. Int J Cancer 2023; 152: 1659-1667.","DOI":"10.1002\/ijc.34326"},{"key":"ref170","doi-asserted-by":"publisher","unstructured":"Davis KL, Fox E, Isikwei E, Reid JM, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ and Mackall CL. A phase I\/II trial of nivolumab plus ipilimumab in Children and young adults with relapsed\/refractory solid tumors: a Children’s oncology group study ADVL1412. Clin Cancer Res 2022; 28: 5088-5097.","DOI":"10.1158\/1078-0432.CCR-22-2164"},{"key":"ref171","doi-asserted-by":"publisher","unstructured":"Metts JL, Trucco M, Weiser DA, Thompson P, Sandler E, Smith T, Crimella J, Sansil S, Thapa R, Fridley BL, Llosa N, Badgett T, Gorlick R, Reed D and Gill J. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: a report from the national pediatric cancer foundation. Cancer Med 2023; 12: 4270-4281.","DOI":"10.1002\/cam4.5297"},{"key":"ref172","doi-asserted-by":"publisher","unstructured":"Attia S, Bolejack V, Ganjoo KN, George S, Agulnik M, Rushing D, Loggers ET, Livingston MB, Wright J, Chawla SP, Okuno SH, Reinke DK, Riedel RF, Davis LE, Ryan CW and Maki RG. A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results. Cancer Med 2023; 12: 1532-1539.","DOI":"10.1002\/cam4.5044"},{"key":"ref173","doi-asserted-by":"publisher","unstructured":"Saulnier-Sholler G, Duda DG, Bergendahl G, Ebb D, Snuderl M, Laetsch TW, Michlitsch J, Hanson D, Isakoff MS, Bielamowicz K, Kraveka JM, Ferguson W, Carmeliet P, De Deene A, Gijsen L and Jain RK. A phase I trial of TB-403 in Relapsed medulloblastoma, neuroblastoma, Ewing sarcoma, and alveolar rhabdomyosarcoma. Clin Cancer Res 2022; 28: 3950-3957.","DOI":"10.1158\/1078-0432.CCR-22-1169"},{"key":"ref174","doi-asserted-by":"publisher","unstructured":"Subbiah V, Braña I, Longhi A, Boni V, Delord JP, Awada A, Boudou-Rouquette P, Sarantopoulos J, Shapiro GI, Elias A, Ratan R, Fernandez C, Kahatt C, Cullell-Young M, Siguero M, Zeaiter A and Chawla SP. Antitumor activity of lurbinectedin, a selective inhibitor of oncogene transcription, in patients with relapsed Ewing sarcoma: results of a basket phase II study. Clin Cancer Res 2022; 28: 2762-2770.","DOI":"10.1158\/1078-0432.CCR-22-0696"},{"key":"ref175","doi-asserted-by":"publisher","unstructured":"Sparber-Sauer M, Ferrari A, Kosztyla D, Ladenstein R, Cecchetto G, Kazanowska B, Scarzello G, Ljungman G, Milano GM, Niggli F, Alaggio R, Vokuhl C, Casanova M, Klingebiel T, Zin A, Koscielniak E and Bisogno G. Long-term results from the multicentric European randomized phase 3 trial CWS\/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults. Pediatr Blood Cancer 2022; 69: e29691.","DOI":"10.1002\/pbc.29691"},{"key":"ref176","doi-asserted-by":"publisher","unstructured":"Koch R, Gelderblom H, Haveman L, Brichard B, Jürgens H, Cyprova S, van den Berg H, Hassenpflug W, Raciborska A, Ek T, Baumhoer D, Egerer G, Eich HT, Renard M, Hauser P, Burdach S, Bovee J, Bonar F, Reichardt P, Kruseova J, Hardes J, Kühne T, Kessler T, Collaud S, Bernkopf M, Butterfaß-Bahloul T, Dhooge C, Bauer S, Kiss J, Paulussen M, Hong A, Ranft A, Timmermann B, Rascon J, Vieth V, Kanerva J, Faldum A, Metzler M, Hartmann W, Hjorth L, Bhadri V and Dirksen U. High-dose treosulfan and melphalan as consolidation therapy versus standard therapy for high-risk (metastatic) Ewing sarcoma. J Clin Oncol 2022; 40: 2307-2320.","DOI":"10.1200\/JCO.21.01942"},{"key":"ref177","doi-asserted-by":"publisher","unstructured":"Leavey PJ, Laack NN, Krailo MD, Buxton A, Randall RL, DuBois SG, Reed DR, Grier HE, Hawkins DS, Pawel B, Nadel H, Womer RB, Letson GD, Bernstein M, Brown K, Maciej A, Chuba P, Ahmed AA, Indelicato DJ, Wang D, Marina N, Gorlick R, Janeway KA and Mascarenhas L. phase III trial adding vincristine-topotecan-cyclophosphamide to the initial treatment of patients with nonmetastatic ewing sarcoma: a children’s oncology group report. J Clin Oncol 2021; 39: 4029-4038.","DOI":"10.1200\/JCO.21.00358"},{"key":"ref178","doi-asserted-by":"publisher","unstructured":"Xu J, Xie L, Sun X, Liu K, Tang X, Yan T, Yang R, Guo W and Gu J. Anlotinib, vincristine, and irinotecan for advanced Ewing sarcoma after failure of standard multimodal therapy: a two-cohort, phase Ib\/II trial. Oncologist 2021; 26: e1256-e1262.","DOI":"10.1002\/onco.13726"},{"key":"ref179","doi-asserted-by":"publisher","unstructured":"Bukowinski A, Chang B, Reid JM, Liu X, Minard CG, Trepel JB, Lee MJ, Fox E and Weigel BJ. A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN). Pediatr Blood Cancer 2021; 68: e28892.","DOI":"10.1002\/pbc.28892"},{"key":"ref180","doi-asserted-by":"publisher","unstructured":"Ono A, Murakami H, Seto T, Shimizu T, Watanabe S, Takeshita S, Takeda K, Toyoshima J, Nagase I, Bahceci E, Morishita M, Morita S, Fukuoka M and Nakagawa K. Safety and antitumor activity of repeated ASP3026 administration in Japanese patients with solid tumors: a phase I study. Drugs R D 2021; 21: 65-78.","DOI":"10.1007\/s40268-020-00331-2"},{"key":"ref181","doi-asserted-by":"publisher","unstructured":"Chugh R, Ballman KV, Helman LJ, Patel S, Whelan JS, Widemann B, Lu Y, Hawkins DS, Mascarenhas L, Glod JW, Ji J, Zhang Y, Reinke D and Strauss SJ. SARC025 arms 1 and 2: a phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. Cancer 2021; 127: 1301-1310.","DOI":"10.1002\/cncr.33349"},{"key":"ref182","doi-asserted-by":"publisher","unstructured":"Federico SM, Pappo AS, Sahr N, Sykes A, Campagne O, Stewart CF, Clay MR, Bahrami A, McCarville MB, Kaste SC, Santana VM, Helmig S, Gartrell J, Shelat A, Brennan RC, Hawkins D, Godwin K, Bishop MW, Furman WL and Stewart E. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. Eur J Cancer 2020; 137: 204-213.","DOI":"10.1016\/j.ejca.2020.06.014"},{"key":"ref183","doi-asserted-by":"publisher","unstructured":"Amoroso L, Castel V, Bisogno G, Casanova M, Marquez-Vega C, Chisholm JC, Doz F, Moreno L, Ruggiero A, Gerber NU, Fagioli F, Hingorani P, Melcón SG, Slepetis R, Chen N, le Bruchec Y, Simcock M and Vassal G. Phase II results from a phase I\/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: a collaboration with the European innovative therapies for children with cancer network. Eur J Cancer 2020; 135: 89-97.","DOI":"10.1016\/j.ejca.2020.04.031"},{"key":"ref184","doi-asserted-by":"publisher","unstructured":"Oesterheld JE, Reed DR, Setty BA, Isakoff MS, Thompson P, Yin H, Hayashi M, Loeb DM, Smith T, Makanji R, Fridley BL and Wagner LM. Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: a report from the national pediatric cancer foundation. Pediatr Blood Cancer 2020; 67: e28370.","DOI":"10.1002\/pbc.28370"},{"key":"ref185","doi-asserted-by":"publisher","unstructured":"Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ and Mackall CL. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol 2020; 21: 541-550.","DOI":"10.1016\/S1470-2045(20)30023-1"},{"key":"ref186","doi-asserted-by":"publisher","unstructured":"Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, Chevreau C, Duffaud F, Entz-Werlé N, Saada E, Ray-Coquard I, Lervat C, Gaspar N, Marec-Berard P, Pacquement H, Wright J, Toulmonde M, Bessede A, Crombe A, Kind M, Bellera C and Blay JY. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2020; 21: 446-455.","DOI":"10.1016\/S1470-2045(19)30825-3"},{"key":"ref187","doi-asserted-by":"publisher","unstructured":"Chin M, Yokoyama R, Sumi M, Okita H, Kawai A, Hosono A, Koga Y, Sano H, Watanabe H, Ozaki T and Mugishima H; Japan Ewing Sarcoma Study Group (JESS). Multimodal treatment including standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for the Ewing sarcoma family of tumors in Japan: results of the Japan Ewing Sarcoma Study 04. Pediatr Blood Cancer 2020; 67: e28194.","DOI":"10.1002\/pbc.28194"},{"key":"ref188","doi-asserted-by":"publisher","unstructured":"Qayed M, Cash T, Tighiouart M, MacDonald TJ, Goldsmith KC, Tanos R, Kean L, Watkins B, Suessmuth Y, Wetmore C and Katzenstein HM. A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors. Pediatr Blood Cancer 2020; 67: e28134.","DOI":"10.1002\/pbc.28134"},{"key":"ref189","doi-asserted-by":"publisher","unstructured":"Cole KA, Pal S, Kudgus RA, Ijaz H, Liu X, Minard CG, Pawel BR, Maris JM, Haas-Kogan DA, Voss SD, Berg SL, Reid JM, Fox E and Weigel BJ. Phase I clinical trial of the Wee1 inhibitor adavosertib (AZD1775) with Irinotecan in Children with relapsed solid tumors: A COG phase I consortium report (ADVL1312). Clin Cancer Res 2020; 26: 1213-1219.","DOI":"10.1158\/1078-0432.CCR-19-3470"},{"key":"ref190","doi-asserted-by":"publisher","unstructured":"Schafer ES, Rau RE, Berg SL, Liu X, Minard CG, Bishop AJR, Romero JC, Hicks MJ, Nelson MD Jr, Voss S, Reid JM, Fox E, Weigel BJ and Blaney SM. Phase 1\/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory\/recurrent solid tumors including Ewing sarcoma: a Children’s on-cology group phase 1 consortium study (ADVL1411). Pediatr Blood Cancer 2020; 67: e28073.","DOI":"10.1002\/pbc.28073"},{"key":"ref191","doi-asserted-by":"publisher","unstructured":"Ash S, Yaniv I, Toledano H, Stein J, Kollender Y, Fenig E, Konen O, Bar-Sever Z, Issakov J, Avigad S and Cohen IJ. Improved outcome in local Ewing sarcoma with an intensified pilot treatment protocol SCMCIE 94. J Pediatr Hematol Oncol 2019; 41: 105-111.","DOI":"10.1097\/MPH.0000000000001384"},{"key":"ref192","doi-asserted-by":"publisher","unstructured":"Geller JI, Fox E, Turpin BK, Goldstein SL, Liu X, Minard CG, Kudgus RA, Reid JM, Berg SL and Weigel BJ. A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: a Children’s oncology group phase 1 and pilot consortium trial (ADVL1315). Cancer 2018; 124: 4548-4555.","DOI":"10.1002\/cncr.31725"},{"key":"ref193","doi-asserted-by":"publisher","unstructured":"Moreno L, Casanova M, Chisholm JC, Berlanga P, Chastagner PB, Baruchel S, Amoroso L, Gallego Melcón S, Gerber NU, Bisogno G, Fagioli F, Geoerger B, Glade Bender JL, Aerts I, Bergeron C, Hingorani P, Elias I, Simcock M, Ferrara S, Le Bruchec Y, Slepetis R, Chen N and Vassal G. Phase I results of a phase I\/II study of weekly nab-paclitaxel in paediatric patients with recurrent\/refractory solid tumours: a collaboration with innovative therapies for children with cancer. Eur J Cancer 2018; 100: 27-34.","DOI":"10.1016\/j.ejca.2018.05.002"},{"key":"ref194","doi-asserted-by":"publisher","unstructured":"Schafer ES, Rau RE, Berg S, Liu X, Minard CG, D’Adamo D, Scott R, Reyderman L, Martinez G, Devarajan S, Reid JM, Fox E, Weigel BJ and Blaney SM. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: a Children’s oncology group phase 1 consortium study (ADVL1314). Pediatr Blood Cancer 2018; 65: e27066.","DOI":"10.1002\/pbc.27066"},{"key":"ref195","doi-asserted-by":"publisher","unstructured":"Chuk MK, Widemann BC, Minard CG, Liu X, Kim A, Bernhardt MB, Kudgus RA, Reid JM, Voss SD, Blaney S, Fox E and Weigel BJ. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: trial ADVL1211, a report from the Children’s oncology group. Pediatr Blood Cancer 2018; 65: e27077.","DOI":"10.1002\/pbc.27077"},{"key":"ref196","doi-asserted-by":"publisher","unstructured":"Norris RE, Fox E, Reid JM, Ralya A, Liu XW, Minard C and Weigel BJ. Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: a report from the Children’s oncology group phase 1 pilot consortium (ADVL1213). Pediatr Blood Cancer 2018; 65: e26944.","DOI":"10.1002\/pbc.26944"},{"key":"ref197","doi-asserted-by":"publisher","unstructured":"Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D’Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D and Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017; 18: 1493-1501.","DOI":"10.1016\/S1470-2045(17)30624-1"},{"key":"ref198","doi-asserted-by":"publisher","unstructured":"Mora J, Castañeda A, Perez-Jaume S, Lopez-Pousa A, Maradiegue E, Valverde C, Martin-Broto J, Garcia Del Muro X, Cruz O, Cruz J, Martinez-Trufero J, Maurel J, Vaz MA, de Alava E and de Torres C. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS). Br J Cancer 2017; 117: 767-774.","DOI":"10.1038\/bjc.2017.252"},{"key":"ref199","doi-asserted-by":"publisher","unstructured":"Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, Figg WD, Whitcomb P, Helman LJ and Widemann BC. A phase I\/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. Cancer Chemother Pharmacol 2017; 80: 645-652.","DOI":"10.1007\/s00280-017-3382-x"},{"key":"ref200","doi-asserted-by":"publisher","unstructured":"Becher OJ, Millard NE, Modak S, Kushner BH, Haque S, Spasojevic I, Trippett TM, Gilheeney SW, Khakoo Y, Lyden DC, De Braganca KC, Kolesar JM, Huse JT, Kramer K, Cheung NV and Dunkel IJ. A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. PLoS One 2017; 12: e0178593.","DOI":"10.1371\/journal.pone.0178593"},{"key":"ref201","doi-asserted-by":"publisher","unstructured":"Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, Monge OR, Lassaletta A, Boldrini E, Pápai Z, Rubino J, Pathiraja K, Hille DA, Ayers M, Yao SL, Nebozhyn M, Lu B and Mauro D. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer 2016; 63: 1761-70.","DOI":"10.1002\/pbc.26087"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/3\/ajtr0160783.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:50:54Z","timestamp":1766022654000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/3\/ajtr0160783.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":202,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/ymeu1808","relation":{},"ISSN":["1943-8141"],"issn-type":[{"type":"electronic","value":"1943-8141"}],"subject":[],"published":{"date-parts":[[2025]]}}}